Page last updated: 2024-09-04

atrasentan and tezosentan

atrasentan has been researched along with tezosentan in 2 studies

Compound Research Comparison

Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)	Studies (tezosentan)	Trials (tezosentan)	Recent Studies (post-2010) (tezosentan)
358	41	108	157	29	33

Protein Interaction Comparison

Protein	Taxonomy	atrasentan (IC50)	tezosentan (IC50)
Endothelin receptor type B	Homo sapiens (human)		0.021
Endothelin-1 receptor	Homo sapiens (human)		0.0205

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ	1
Cheng, G; Li, B; Li, Y; Liu, D; Lu, S; Xiao, J; Yuan, W; Zhao, Z	1

Reviews

1 review(s) available for atrasentan and tezosentan

Article	Year
Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis. Blood pressure, 2017, Volume: 26, Issue:3 Topics: Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension; Middle Aged; Models, Statistical; Phenylpropionates; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Tetrazoles	2017

Article

Year

Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.

Blood pressure, 2017, Volume: 26, Issue:3

Topics: Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension; Middle Aged; Models, Statistical; Phenylpropionates; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Tetrazoles

2017

Trials

1 trial(s) available for atrasentan and tezosentan

Article	Year
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8 Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones	2004

Article

Year

Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.

Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8

Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones

2004